1-aminomethyl-5,6-dihydroxy-3-phenylisochroman; NMDA antagonist; CPP; 3-((6)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease
✍ Scribed by Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 247 KB
- Volume
- 179
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The clinical symptoms of Parkinson's disease (PD) appear late and only when the degenerative process at the level of the nigrostriatal dopamine (DA) pathway is quite advanced. An increase in brain‐derived neurotrophic factor (BDNF) expression may be one of the molecular signals associat
## Abstract This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6‐hydroxydopamine (6‐OHDA) (a “classic” model of Parkinson's disease, PD), and to evaluate whe
## Abstract Dopaminergic (DA) grafts in rat models of Parkinson's disease (PD) have previously been derived from embryonic day (E) 14 grafts. Because there is an increasing interest in the restorative capacity of DA stem and progenitor cells, in the present study we examined the survival and early
## Abstract In this study, we examined the interaction of 5‐HT~1A~ and 5‐HT~2A~ receptors in the rat medial prefrontal cortex (mPFc) using the techniques of extracellular single unit recording and microiontophoresis. The iontophoresis of the selective 5‐HT~1A~ receptor agonist (±)‐8‐hydroxy‐2‐(di‐n